{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:40:03Z","timestamp":1792798803263,"version":"4.5.0"},"reference-count":43,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["320030_189140 \/ 1"],"award-info":[{"award-number":["320030_189140 \/ 1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Health and Labour Sciences Research Grant on Intractable Diseases (Neuroimmunological Diseases) from the Ministry of Health, Labour and Welfare of Japan","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}],"id":[{"id":"https:\/\/ror.org\/03mwa7s65","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Swedish MRC","award":["2020-02700, Hj\u00e4rnfonden"],"award-info":[{"award-number":["2020-02700, Hj\u00e4rnfonden"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2023,3,21]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Granulocyte invasion into the brain is a pathoanatomical feature differentiating neuromyelitis optica spectrum disorder (NMOSD) from multiple sclerosis (MS). We aimed to determine whether granulocyte activation markers (GAM) in cerebrospinal fluid (CSF) can be used as a biomarker to distinguish NMOSD from MS, and whether levels associate with neurological impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We quantified CSF levels of five GAM (neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin, matrixmetalloproteinase-8, tissue inhibitor of metalloproteinase-1), as well as a set of inflammatory and tissue-destruction markers, known to be upregulated in NMOSD and MS (neurofilament light chain, glial fibrillary acidic protein, S100B, matrix metalloproteinase-9, intercellular adhesion molecule-1, vascular cellular adhesion molecule-1), in two cohorts of patients with mixed NMOSD and relapsing-remitting multiple sclerosis (RRMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In acute NMOSD, GAM and adhesion molecules, but not the other markers, were higher than in RRMS and correlated with actual clinical disability scores. Peak GAM levels occurred at the onset of NMOSD attacks, while they were stably low in MS, allowing to differentiate the two diseases for \u226421 days from onset of clinical exacerbation. Composites of GAM provided area under the curve values of 0.90\u20130.98 (specificity of 0.76\u20131.0, sensitivity of 0.87\u20131.0) to differentiate NMOSD from MS, including all anti-aquaporin-4 protein (aAQP4)-antibody-negative patients who were untreated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      GAM composites represent a novel biomarker to reliably differentiate NMOSD from MS, including in aAQP4\n                      <jats:sup>\u2212<\/jats:sup>\n                      NMOSD. The association of GAM with the degree of concurrent neurological impairment provides evidence for their pathogenic role, in turn suggesting them as potential drug targets in acute NMOSD.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2022-330796","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T13:21:02Z","timestamp":1681910462000},"page":"726-737","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Granulocyte activation markers in cerebrospinal fluid differentiate acute neuromyelitis spectrum disorder from multiple sclerosis"],"prefix":"10.1136","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-801X","authenticated-orcid":false,"given":"David","family":"Leppert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0831-623X","authenticated-orcid":false,"given":"Mitsuru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-0962","authenticated-orcid":false,"given":"Sabine","family":"Schaedelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8329-5219","authenticated-orcid":false,"given":"Fredrik","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7376-9425","authenticated-orcid":false,"given":"Roberto","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2288-2000","authenticated-orcid":false,"given":"Matteo","family":"Gastaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-9619","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Evertsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0030-0236","authenticated-orcid":false,"given":"Katharina","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Matsushita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2516-1102","authenticated-orcid":false,"given":"Katsuhisa","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9525-4254","authenticated-orcid":false,"given":"Noriko","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5307-2671","authenticated-orcid":false,"given":"Jun-ichi","family":"Kira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-8174","authenticated-orcid":false,"given":"Pascal","family":"Benkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1916-5927","authenticated-orcid":false,"given":"Aleksandra","family":"Maceski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-4243","authenticated-orcid":false,"given":"Eline","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5359-7961","authenticated-orcid":false,"given":"Johanna","family":"Oechtering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Orleth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-4203","authenticated-orcid":false,"given":"Stephanie","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-8892","authenticated-orcid":false,"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"June","key":"2024102910301111000_94.9.726.1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3389\/fneur.2020.00450","article-title":"Visualizing the central nervous system: imaging tools for multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"11","author":"Kuchling","year":"2020","journal-title":"Front Neurol"},{"key":"2024102910301111000_94.9.726.2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-017-8596-7"},{"key":"2024102910301111000_94.9.726.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2011.03.038"},{"issue":"March","key":"2024102910301111000_94.9.726.4","doi-asserted-by":"crossref","first-page":"635419","DOI":"10.3389\/fneur.2021.635419","article-title":"Anti-aquaporin 4 igG is not associated with any clinical disease characteristics in neuromyelitis optica spectrum disorder","volume":"12","author":"Schmetzer","year":"2021","journal-title":"Front Neurol"},{"key":"2024102910301111000_94.9.726.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7952-8"},{"key":"2024102910301111000_94.9.726.6","doi-asserted-by":"crossref","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","article-title":"Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD","volume":"93","author":"Watanabe","year":"2019","journal-title":"Neurology"},{"key":"2024102910301111000_94.9.726.7","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5381239","article-title":"CSF-S100B is a potential candidate biomarker for neuromyelitis optica spectrum disorders","volume":"2018","author":"Wei","year":"2018","journal-title":"Biomed Res Int"},{"issue":"January 2019","key":"2024102910301111000_94.9.726.8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jocn.2020.11.016","article-title":"High serum neurofilament levels among chinese patients with aquaporin-4-igG-seropositive neuromyelitis optica spectrum disorders","volume":"83","author":"Liu","year":"2021","journal-title":"J Clin Neurosci"},{"key":"2024102910301111000_94.9.726.9","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.648","article-title":"Elevated C-X-C motif ligand 13 and B-cell-activating factor levels in neuromyelitis optica during remission","volume":"7","author":"Wang","year":"2017","journal-title":"Brain Behav"},{"key":"2024102910301111000_94.9.726.10","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512473362"},{"key":"2024102910301111000_94.9.726.11","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510389102"},{"key":"2024102910301111000_94.9.726.12","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.148"},{"key":"2024102910301111000_94.9.726.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.04.009"},{"key":"2024102910301111000_94.9.726.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf151"},{"key":"2024102910301111000_94.9.726.15","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12099"},{"key":"2024102910301111000_94.9.726.16","doi-asserted-by":"crossref","DOI":"10.1172\/JCI141694","article-title":"Blood-Brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration","volume":"131","author":"Winkler","year":"2021","journal-title":"J Clin Invest"},{"key":"2024102910301111000_94.9.726.17","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab102"},{"issue":"February","key":"2024102910301111000_94.9.726.18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3389\/fneur.2020.00031","article-title":"A fulminant case of demyelinating encephalitis with extensive cortical involvement associated with anti-MOG antibodies","volume":"11","author":"Hochmeister","year":"2020","journal-title":"Front Neurol"},{"key":"2024102910301111000_94.9.726.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02132-y"},{"key":"2024102910301111000_94.9.726.20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000001149","article-title":"Cell-Free DNA derived from neutrophils triggers type 1 interferon signature in neuromyelitis optica spectrum disorder","volume":"9","author":"Murata","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301111000_94.9.726.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001729"},{"key":"2024102910301111000_94.9.726.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2024102910301111000_94.9.726.23","unstructured":"Neurostatus-UHB ltd c\/o university hospital basel switzerland. 2016. Available: www.neurostatus.net"},{"key":"2024102910301111000_94.9.726.24","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513488232"},{"key":"2024102910301111000_94.9.726.25","doi-asserted-by":"crossref","first-page":"6398","DOI":"10.4049\/jimmunol.161.11.6398","article-title":"Proteolytic cleavage of ICAM-1 by human neutrophil elastase","volume":"161","author":"Champagne","year":"1998","journal-title":"J Immunol"},{"key":"2024102910301111000_94.9.726.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1289"},{"key":"2024102910301111000_94.9.726.27","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01028"},{"key":"2024102910301111000_94.9.726.28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000626","article-title":"Classifying the antibody-negative NMO syndromes: clinical, imaging, and metabolomic modeling","volume":"6","author":"Yeo","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301111000_94.9.726.29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","article-title":"Serum GFAP and NFL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder","volume":"18","author":"Schindler","year":"2021","journal-title":"J Neuroinflammation"},{"key":"2024102910301111000_94.9.726.30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/1744666X.2023.2148657","article-title":"Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review","volume":"19","author":"Schindler","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"2024102910301111000_94.9.726.31","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1089\/biores.2020.0012","article-title":"Joint measurements of leukocyte elastase and myeloperoxidase promote identification of the state of neutrophils in diabetic patients","volume":"9","author":"Alexandrovski","year":"2020","journal-title":"Biores Open Access"},{"key":"2024102910301111000_94.9.726.32","unstructured":"Mayo Clinical Laboratories . Neuromyelitis optica (NMO)\/aquaporin-4-igG fluorescence-activated cell sorting (FACS) assay serum [internet]. 2021. Available: https:\/\/www.mayocliniclabs.com\/test-catalog\/Overview\/38324"},{"key":"2024102910301111000_94.9.726.33","unstructured":"Oxford University Hospitals. Neuromyelitis Optica Antibodies [Internet] 2021. Available: https:\/\/www.ouh.nhs.uk\/immunology\/diagnostic-tests\/tests-catalogue\/neuromyelitis-optica-antibodies.aspx"},{"key":"2024102910301111000_94.9.726.34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301111000_94.9.726.35","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024102910301111000_94.9.726.36","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-316286"},{"issue":"February","key":"2024102910301111000_94.9.726.37","doi-asserted-by":"crossref","first-page":"841051","DOI":"10.3389\/fped.2022.841051","article-title":"Case report: atypical HUS presenting with acute rhabdomyolysis highlights the need for individualized eculizumab dosing","volume":"10","author":"Benoit","year":"2022","journal-title":"Front Pediatr"},{"key":"2024102910301111000_94.9.726.38","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.951423","article-title":"Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report","volume":"13","author":"Chatterton","year":"2022","journal-title":"Front Neurol"},{"key":"2024102910301111000_94.9.726.39","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22686"},{"key":"2024102910301111000_94.9.726.40","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22551"},{"key":"2024102910301111000_94.9.726.41","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512440060"},{"key":"2024102910301111000_94.9.726.42","unstructured":"Leppert D . Potential of neutrophil granulocyte markers in CSF to differentiate NMOSD and MOGAD from MS [internet]. in: MS virtual 2020. 2020. Available: https:\/\/touchneurology.com\/multiple-sclerosis\/conference-hub\/david-leppert-msvirtual2020-potential-of-neutrophil-granulocyte-markers-in-csf-to-differentiate-nmosd-and-mogad-from-ms\/"},{"key":"2024102910301111000_94.9.726.43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801466"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2022-330796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,29]],"date-time":"2024-10-29T13:30:46Z","timestamp":1730208646000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2022-330796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,26]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1136\/jnnp-2022-330796"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2022-330796","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]}}}